Megamin is much better product than Panaceo – Basic Detox and Detoxamin – Basic farina, Lifeplus and Forever living



Clinical Effect Observation and Patient Monitoring In the beginning of the year 1999 we started with the application of Megamin/TMAZA (tribomechanically activated zeolite) in tumor patients at our Department, then still dealing with insufficient knowledge of the institutional research by "Ruđer Bošković". According to the technical-technological information by the Megamin manufacturer, the company of Tribomin Internationald.o.o., Osijek, Croatia, the Megamin products from the Megamin group are specially prepared food supplement showing strong antioxidant activity and stimulating the immune system in the organisms of healthy and sick persons.


Our raw materials are better than competitors offer Panaceo, Detoxamin, Energetix, Lifeplus, Foreverliving!


The main raw material for the production of the preparations shown below is a rocky mineral of volcanic origin - clinoptolite known as a natural ion exchanger belonging to the zeolite mineral group.


During the production process this natural mineral is subjected to the process of tribomechanical micronization, by which reactivity and the known natural characteristics of that mineral are increased.


Other natural ingredients known for their beneficial effect such as calcium, magnesium, pollen and/or dried nettle are added to the mineral, so that there are the following preparations in the market:


Megamin Powder

Megamin Capsules  

Megamin Plus

Megamin Forte


Megamin offers more than competitors Panaceo, Detoxamin (Energetix):


At the beginning we were administering the Megamin preparations as an "ultimatum refugium" (last hope) in our ante finem patients with open metastases of lymph glands in the neck. Our first experiences were rather encouraging. It was established that metastases were rapidly "melting" and decreasing and the metastasis bleeding stops, but nevertheless the sickness was still progressing and was leading to the end of the life path, only the quality of life in those last days was significantly improved. After such observations we started to administer TMAZ in patients with:


- paranasal sinuses cancer;

- mouth cavity cancer

- tong cancer

- salivary glands cancer (subtongue, subjaw)

- pharynx cancer

- larynx cancer

- metastazing cancer in the neck


During the administering of Megamin clinical and lab observations and monitoring were performed on our patients at the same time. The observation consisted of the following parameters:


- blood count and sedimentation

- serological tests

- biochemical tests

- tumor markers: CA125, CA19.9, CEA, SCC, TPA, Cyfra

- conventional X-ray examinations (lung X-ray, sinus X-ray)

- CT examinations

- MR examinations

- PET (Positron Emission Tomography) examinations,


Which are an especially good examination for finding and monitoring of metastases (increase/decrease) and their location in the patient's body, which is important for further prognosis and treatment course. Tumor anemia was observed in 92% cases. Transaminase and CRP values are increased in a high percentage and represent an almost regular rule in the patients with malignancies. The tumor markers SCC, CA 19.9 and Cyfra (19 fragment Cytokeratin) in planocellular cancer of head and neck are 10 to 15 times increased.


By a CT examination and especially by a MR examination, tumor location, size and progress, and tissue destruction are exactly established, which is extremely important for further surgical treatment, as well as during the postoperative control. In the majority of our tumor patients, adjuvant Megamin therapy is in most cases included in the first e.g. the second week following the surgery. In the beginning we were avoiding administering during chemotherapy.